Vedolizumab SC

Takeda is running a Phase 3 pharmacokinetic bridging study of vedolizumab in children and adolescents with moderately to severely active ulcerative colitis (UC) or Crohn's disease (NCT06100289) [1]. Vedolizumab, sold as Entyvio, is Takeda's largest single product, generating JPY 914.1 billion (approximately $6.1B USD at prevailing exchange rates) in FY2025 (year ended March 2026) [7], and holds adult FDA approvals in both IBD indications since 2014 [2]. The subcutaneous auto-injector formulation gained adult UC maintenance approval in September 2023 and adult CD maintenance approval in April 2024. This pediatric trial (n=70) is a small open-label bridging study designed to match adult drug exposure levels in children, supporting a supplemental label expansion into ages 2 to 17. It builds directly on the Phase 2 HUBBLE study (NCT03138655), which established pediatric IV vedolizumab PK, safety, and clinical response in the same age range [8]. The commercial dollars added by a pediatric label are modest, but the strategic value is real: capturing pediatric IBD patients builds a lifelong prescription base and blunts share loss to newer entrants like risankizumab and upadacitinib. Scientific risk on this specific trial is low. The bigger questions for Entyvio's future are the imminent IV biosimilar cliff (Alvotech's AVT16 BLA accepted June 2026 [9], Polpharma/Fresenius Kabi's PB016 BLA accepted July 2026 [10]) and AbbVie's Phase 3 head-to-head trial (NCT06880744) of risankizumab vs vedolizumab in biologic-naive adult UC [3].

Vedolizumab is an approved biologic, not an investigational compound. FDA first approved it in May 2014 (BLA 125476) as an intravenous infusion for adult moderate-to-severe UC and CD [2]. The subcutaneous auto-injector formulation was approved for adult UC maintenance in September 2023 and adult CD maintenance in April 2024. NCT06100289 is a Phase 3 open-label study in children ages 2 to 17 with active UC or CD, sponsored by Takeda and currently recruiting [1]. Primary endpoint is steady-state trough concentration (Ctrough,ss) at Week 34, a PK match to adult exposures rather than an efficacy readout. The Phase 2 HUBBLE study (NCT03138655) already established pediatric IV vedolizumab PK, safety, and efficacy at Week 14 in ages 2 to 17 [8]; that precedent is the direct evidentiary basis for using a bridging design here rather than running a full placebo-controlled pediatric efficacy trial. This is the standard regulatory pathway for pediatric label extensions of established biologics: sponsors show the drug reaches the same blood levels in kids as in adults, and extrapolate adult efficacy data. No breakthrough therapy or fast track designation applies, since vedolizumab is not novel. Timeline for readout is not publicly disclosed, but Phase 3 pediatric IBD enrollment historically takes 3 to 4 years, so a supplemental BLA filing is plausible in 2027 to 2028.

Vedolizumab is a monoclonal antibody that blocks α4β7 integrin, a receptor on the surface of memory T lymphocytes that acts as a homing beacon for gut tissue [4]. Think of α4β7 as a zip code stamp: white blood cells wearing it get routed specifically to the intestinal lining. In IBD, too many inflammatory immune cells traffic to the gut, where they attack the bowel wall and cause the ulcers, bleeding, and diarrhea that define UC and CD. Vedolizumab blocks α4β7 from binding to its docking partner MAdCAM-1, which is expressed almost exclusively on gut blood vessels. The result: inflammatory cells stay in circulation and never reach the bowel wall. This gut selectivity is the drug's core clinical and commercial advantage. Unlike TNF inhibitors such as adalimumab and infliximab, which suppress inflammation systemically and raise infection risk broadly, vedolizumab acts only in the gut. Unlike natalizumab, an older α4-integrin blocker that hits both α4β1 (which routes cells to the brain) and α4β7, vedolizumab does not carry the PML (progressive multifocal leukoencephalopathy) risk that made natalizumab a niche MS drug. The mechanism is validated by ten years of adult IBD use, billions in revenue, and consistent real-world remission data [5].

NCT06100289 is a Phase 3 open-label, multicenter PK study of vedolizumab SC in 70 pediatric patients ages 2 to 17 with moderately to severely active UC or CD [1]. Sponsor is Takeda. Primary endpoint is Ctrough,ss at Week 34, meaning the steady-state blood level of drug measured just before the next dose. Secondary endpoints include clinical remission on standard pediatric activity indices (Pediatric Ulcerative Colitis Activity Index, or PUCAI, for UC; Pediatric Crohn's Disease Activity Index, or PCDAI, for CD), safety, and immunogenicity (formation of anti-drug antibodies that reduce efficacy over time). The design leans directly on the Phase 2 HUBBLE study (NCT03138655), which showed IV vedolizumab in children ages 2 to 17 produced dose-proportional serum exposure and clinical response comparable to adult GEMINI-era data [8]; that precedent is why the SC study can rely on PK matching rather than a full placebo-controlled efficacy trial. Design rationale is otherwise pragmatic. Pediatric IBD affects far fewer patients than adult IBD, and running a placebo-controlled efficacy trial in kids with active disease is neither ethical nor logistically feasible when adult efficacy is well-established. Concerns are limited but real. Weight-based dosing may need adjustment across the age range, since a 5-year-old and a 17-year-old have very different pharmacokinetics. Enrollment is slow: pediatric IBD trials routinely take longer than adult trials because the patient pool is small and competes with parallel pediatric expansion trials of adalimumab, infliximab, ustekinumab, and upadacitinib in the same age group. Open-label design means safety signals will be noisy and any efficacy claims will be observational rather than controlled.

Our model estimates a 54% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 61%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by weak or limited earlier-phase results and smaller-than-typical enrollment for this phase. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk on the trial itself is low. The bridging endpoint (Ctrough,ss match) is achievable in pediatric populations with standard weight-based dosing. Safety risk is also low given ten years of adult exposure data, including reassuring long-term infection and malignancy signals. Trial-level risks fall in two buckets. First, PK variability across pediatric weight bands may force dosing adjustments after data lock, complicating the label and requiring additional population pharmacokinetic modeling (statistical analysis of how the drug behaves across patients of different ages, weights, and body compositions). This delays rather than blocks approval. Second, enrollment competition is intense. Pediatric IBD is a small pool, and competing trials for risankizumab, upadacitinib, and mirikizumab are pulling gastroenterologists' attention. Slow enrollment could push readout into 2028 or later. Franchise-level risks are the more material story for investors. The IV biosimilar cliff is now visible. FDA accepted Alvotech's AVT16 aBLA (proposed interchangeable IV vedolizumab biosimilar, partnered with Teva for U.S. commercialization) on June 8, 2026, with an FDA decision expected in Q1 2027 [9]. FDA accepted Polpharma/Fresenius Kabi's PB016 IV vedolizumab biosimilar BLA on July 31, 2026 [10]. Samsung Bioepis and Sandoz publicly signaled a vedolizumab biosimilar development partnership in early 2026. The IV formulation still accounts for the majority of Entyvio revenue, and once biosimilars launch (plausibly 2027 to 2028) IV vedolizumab faces the standard biosimilar erosion curve, which typically cuts originator revenue 30 to 60 percent within a few years of first entrant. Both current BLAs are for the IV lyophilized vial only; no biosimilar targeting the SC auto-injector has been publicly announced. Takeda's SC auto-injector was launched in part to shift the franchise onto a formulation with a longer exclusivity runway (device, formulation, and route-of-administration IP typically extends past base biologic composition-of-matter protection), but Takeda has not publicly disclosed a specific SC exclusivity end date, so the SC 'defense window' should be modeled as an unknown-length buffer rather than a fixed shield. Third franchise risk is head-to-head efficacy. AbbVie's Phase 3 trial (NCT06880744) is an open-label 1:1 randomized comparison of risankizumab vs vedolizumab on endoscopic improvement in approximately 530 adult UC patients, restricted to those naive to targeted therapies (biologic-naive) [3]. The open-label design and biologic-naive restriction limit how definitively a risankizumab win would translate into real-world prescribing shifts, since blinded readers and experienced-line patients behave differently. Even so, if risankizumab wins clearly, gastroenterologists will shift new starts to IL-23 blockade and Entyvio's revenue trajectory bends down further. Recent network meta-analyses already suggest advanced therapies including risankizumab and upadacitinib match or exceed vedolizumab on some efficacy endpoints in adult CD [5]. The pediatric label is worth pursuing but is not the strategic linchpin for this franchise.

Low-stakes watch on this specific trial. NCT06100289 will very likely hit its bridging endpoint and support a pediatric label around 2027 to 2028, adding modest incremental revenue (internal estimate roughly $50 to $100M per year, benchmarked loosely against pediatric label expansions for other IBD biologics; no direct sponsor disclosure exists, and this figure should be treated as an internal estimate rather than a sourced number) but real strategic value in capturing pediatric prescribers who tend to keep patients on the same biologic long-term. The two signals that will actually move Takeda's stock and reshape the IBD biologics competitive picture are both external to this trial. First, the IV biosimilar cliff. Alvotech's AVT16 (Teva-commercialized, interchangeable) FDA decision is expected in Q1 2027 [9]. Polpharma/Fresenius Kabi's PB016 has been under FDA review since July 2026 [10]. Samsung Bioepis/Sandoz is in earlier-stage development. Once one or more launch, IV Entyvio faces the standard biosimilar price and share erosion curve; SC has a longer runway of unknown length. Takeda's mitigation is aggressive SC conversion, and SC uptake trajectory becomes the single most-watchable metric for the franchise. Second, AbbVie's Phase 3 head-to-head (NCT06880744): approximately 530 patients, open-label, 1:1 randomization, restricted to biologic-naive adult UC, endpoint of endoscopic improvement [3]. The open-label and biologic-naive caveats limit how definitively a risankizumab win transfers to real-world prescribing (blinded readouts and experienced-line patients would matter for a full displacement), but this remains the readout most likely to reshape gastroenterologist behavior on new starts. If vedolizumab holds serve on endoscopic endpoints, its gut-selective mechanism story survives another cycle and payer positioning stays intact. For the pediatric study specifically, check back on enrollment progress in late 2026 and on readout in 2027. Also worth watching: MOVE-IT, a model-informed precision-dosing trial of vedolizumab and ustekinumab, which could sharpen response prediction and defend Entyvio's positioning against newer entrants [6].